RBC Capital Markets increased its target price for Oxford Nanopore Technologies to 300p from 225p, citing the company's strong position to benefit from rising demand for biological data driven by AI advancements in drug discovery. Oxford Nanopore's unique sequencing technology provides rich biological data that supports AI models like DeepMind's AlphaGenome. The UK Biobank project, expected to generate significant near-term revenue, and broader opportunities in AI drug discovery underpin RBC's positive outlook despite modest revenue forecast cuts. The target price reflects a valuation premium based on AI-related growth potential.
Oxford Nanopore's target price was raised by RBC on AI opportunities. For readers following the health sector, here is Pluang's market snapshot as of Sep 30, 2026 21:42 WIB: out of 100 priced US health stocks, 38 rose and 62 fell. Notable movers include HIMS at USD 30.45 with a 6.10% increase and a typical hold time on Pluang of 20 days, DNA at USD 12.47 up 4.26%, and INO at USD 1.16 up 4.05%.
Applied Optoelectronics reported an 86% revenue increase to $191.9 million, driven by a 140% surge in data center revenue due to accelerated 800G product adoption. Management aims to reach 650,000 units of 800G and 1.6T capacity monthly by year-end, ...
Royal Caribbean announced its 2028 Alaska cruise lineup featuring 7-night trips on four ships—Anthem, Ovation, Serenade, and Voyager of the Seas—departing from Seattle, Seward, and Vancouver. The cruises offer immersive experiences including glacier ...
Rosen Law Firm has announced an investigation into Beneficient (NASDAQ: BENF) over allegations that the company provided materially misleading business information to investors. Shareholders who purchased Beneficient securities may be eligible for co...
ON Semiconductor is successfully turning around its business with its Fab Right strategy and strong demand from AI data centers and silicon carbide (SiC) products. Management expects AI data center revenue to more than double by 2026, fueling structu...
Conagra Brands reported a 1.4% decline in first-quarter revenue to $2.6 billion, with organic net sales down 1.1%, causing shares to fall 4.6%. Despite the sales drop, adjusted earnings per share rose 5.1% to $0.41, beating analyst estimates of $0.28...
